← Leaderboards
Ho-Young Lee
University Of Texas Md Anderson Can Ctr
$4,801,977
Attributed
$4,801,977
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $625.4K · FY2005–13$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$4,801,977 · 3
By mechanism
R01$3,183,625 · 2
P50$1,618,352 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseSpecimenEpidermal Growth Factor ReceptorDiagnosisTumorMediatingMutationLigandsTumor ProgressionCancer CellPathway InteractionsTissuesLung NeoplasmsSomatomedinsInsulin-Like Growth Factor IReceptorResistanceAdenovirusesMalignant Neoplasm Of LungResponseApoptosisNovel StrategiesGrowthCancer Therapy
Grant awards (19)
Novel Strategy for Lung Cancer Treatment Using IGF-1R Inhibitor$160,786
R01 · FY2013 · CA · contact PI
Targeting EGFR and IGF Axis for Therapy of Head and Neck Squamous Cell Carcinoma$343,462
P50 · FY2012 · CA · contact PI
Novel Strategy for Lung Cancer Treatment Using IGF-1R Inhibitor$171,049
R01 · FY2012 · CA · contact PI
Targeting EGFR and IGF Axis for Therapy of Head and Neck Squamous Cell Carcinoma$345,660
P50 · FY2011 · CA · contact PI
Novel Strategy for Lung Cancer Treatment Using IGF-1R Inhibitor$170,273
R01 · FY2011 · CA · contact PI
Targeting EGFR and IGF Axis for Therapy of Head and Neck Squamous Cell Carcinoma$373,949
P50 · FY2010 · CA · contact PI
Novel Strategy for Lung Cancer Treatment Using IGF-1R Inhibitor$251,447
R01 · FY2010 · CA · contact PI
Targeting EGFR and IGF Axis for Therapy of Head and Neck Squamous Cell Carcinoma$343,830
P50 · FY2009 · CA · contact PI
Novel Strategy for Lung Cancer Treatment Using IGF-1R Inhibitor$251,447
R01 · FY2009 · CA · contact PI
Lung Cancer Chemoprevention using Deguelin$234,808
R01 · FY2008 · CA · contact PI
P-4: Targeting EGFR and the IGF Axis for Therapy of Head and Neck Squamous Cell$211,451
P50 · FY2008 · CA · contact PI
Lung Cancer Chemoprevention using Deguelin$234,808
R01 · FY2007 · CA · contact PI
Novel Strategy for Lung Cancer Treatment using IGFBP-3$234,807
R01 · FY2007 · CA · contact PI
Lung Cancer Chemoprevention using Deguelin$241,820
R01 · FY2006 · CA · contact PI
Novel Strategy for Lung Cancer Treatment using IGFBP-3$241,820
R01 · FY2006 · CA · contact PI
Novel Strategy for Lung Cancer Treatment using IGFBP-3$247,640
R01 · FY2005 · CA
Lung Cancer Chemoprevention using Deguelin$247,640
R01 · FY2005 · CA
Lung Cancer Chemoprevention using Deguelin$247,640
R01 · FY2004 · CA
Novel Strategy for Lung Cancer Treatment using IGFBP-3$247,640
R01 · FY2004 · CA